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Abstract
Purpose Inositol (ISL) embraces a family of simple carbohydrates with insulin-sensitizing properties, whose most common 
isoforms are Myo-inositol (MYO) and d-chiro inositol (DCI). The aim of the present study was to assess the efficacy and 
safety of ISL supplementation during pregnancy for the prevention of gestational diabetes (GDM).
Methods We conducted a systematic literature search in electronic databases until October 2017. We included all randomized 
controlled trials (RCTs) comparing pregnant women with GDM who were randomized to either ISL (i.e., intervention group) 
or either placebo or no treatment (i.e., control group). The primary outcome was the preventive effect on GDM, defined as 
the rate of GDM in women without a prior diagnosis of GDM. Pooled results were expressed as odds ratio (OR) with a 95% 
confidence interval (95% CI).
Results Five RCTs were included (including 965 participants). ISL supplementation was associated with lower rate of GDM 
(OR 0.49, 95% CI 0.24–1.03, p = 0.01) and lower preterm delivery rate (OR 0.35, 95% CI 0.17–0.74, p = 0.006). No adverse 
effects were reported. Adjusting for the type of intervention (MYO 2 g twice daily vs MYO 1100 mg plus DCI 27.6 mg 
daily), a significant effect was found only in patients receiving 2 g MYO twice daily.
Conclusions ISLs administration during pregnancy appears to be safe and may represent a novel strategy for GDM preven-
tion. In particular, the double administration of MYO 2 g per day may improve the glycemic homeostasis and may reduce 
GDM rate and preterm delivery rate.
Keywords Inositol · Gestational diabetes · Diabetes prevention · Preterm delivery · Maternal–fetal health
Introduction
Gestational diabetes mellitus (GDM) is defined as a status 
of glucose intolerance in pregnant women without a previ-
ous diagnosis of diabetes [1]. It affects about 7% of preg-
nant women worldwide and is associated with higher risk of 
pregnancy complications, such as gestational hypertension, 
macrosomia, shoulder dystocia, preterm delivery, cesarean 
delivery, neonatal hypoglycemia and increased perinatal 
mortality [2, 3].
Inositol (ISL) is a sixfold alcohol of cyclohexane that is 
present in animal and plant cells [4, 5]. ISLs family com-
prises nine stereoisomers who are constituent parts of cel-
lular membrane, regulating mitochondria function and dif-
ferent hormonal signaling in the human body [6, 7]. Myo 
inositol (MYO) and d-chiro inositol (DCI), the most com-
mon isoforms of ISL in eukaryotic cells, are characterized by 
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insulin-mimetic properties with potential therapeutic effects 
on insulin-mediated disease [8, 9].
In last years, different studies have investigated the pre-
ventive effects of inositol (ISL) supplementation for GDM 
[8, 10]. Nevertheless, a recent Cochrane review concluded 
that the body of evidence on ISLs effectiveness for this pur-
pose was poor [11]. In last year, two additional randomized 
controlled trials (RCTs) [12, 13] have investigated this topic. 
Thus, the aim of this systematic review and meta-analysis 
was to assess the efficacy and safety of the administration of 
ISLs during pregnancy for the prevention of GDM.
Materials and methods
Study design
This study was conducted according to a protocol designed a 
priori and recommended for systematic review. Review was 
reported following the preferred reporting items for system-
atic reviews and meta-analyses (PRISMA) guidelines [14].
Search strategy
We conducted a systematic literature search in electronic 
databases (Pubmed, Embase, Science direct, the Cochrane 
library, Clinicaltrials.gov, Cochrane Central Register of Con-
trolled Trials, EU Clinical Trials Register and World Health 
Organization International Clinical Trials Registry Platform) 
until October 2017, without date restriction. The Key search 
terms included: inositol OR myo inositol OR d-chiro inositol 
(Mesh/Emtree) AND pregnancy OR gestational diabetes.
No built-in search filters were applied to limit citations 
retrieval. In addition, the reference lists of all identified 
articles were examined to identify studies not captured by 
electronic searches.
Inclusion criteria
We included all randomized controlled trials evaluating the 
effects of ISLs (MYO and/or DCI) administration during 
pregnancy in women at risk of GDM, in whom the control 
group received no intervention or placebo. Studies were 
included if exploring the primary and/or the secondary out-
comes of the review.
Review outcomes
The Primary Outcome was to compare the rate of GDM in 
patients receiving ISLs with patients not receiving interven-
tion (Controls). The Secondary Outcomes were to determine 
the effects of preventive ISL administration on maternal 
and feto-neonatal health, as well as on delivery outcomes. 
Moreover, we evaluated the side effects associated with the 
intervention.
Outcomes measures
• Maternal health outcomes measures:
– GDM rate Defined as the number of patients (%) in 
which GDM was diagnosed.
– Fasting Glucose OGTT (FG-OGTT), 1 h Glucose 
OGTT (1HG-OGTT), 2 h Glucose OGTT (2HG-
OGTT) Defined, respectively, as the mean (mg/dl) 
fasting plasma glucose level, 1-h plasma glucose 
level and 2-h plasma glucose level at OGTT.
– Weight gain at OGTT Defined as the mean weight 
increase (kg) from the start of ISLs assumption to 
OGTT.
– Hypertensive disorders (%) Defined as the occur-
rence of pregnancy-induced hypertension or preec-
lampsia.
– Total cholesterol, LDL, HDL, triglycerides after 
30/60 days Defined as the mean (mg/dl) serum cho-
lesterol, LDL (mg/dl), HDL (mg/dl) and triglycer-
ides (mg/dl) at day 30 and 60 of INSs administration.
– Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) after 30/60 days Defined as the 
mean (mmHg) systolic and diastolic blood pressure 
levels at days 30 and 60 of INSs administration.
• Delivery outcomes measures:
– Cesarean section rate (CS Rate) Defined as the num-
ber of patients (%) in which Cesarean Section was 
performed.
– Preterm delivery (%) Defined as the birth of a baby 
at fewer than 37 weeks gestational age.
– Shoulder dystocia (%) Defined as the occurrence of 
shoulder dystocia during labor.
– Third degree perineal tear (%) Defined as the lacera-
tion of external anal sphincter.
• Feto-neonatal health outcomes measures:
– Gestational age at birth (GA at birth) Defined as the 
days of gestation (mean) at the time of delivery.
– Birth weight Defined as the mean neonatal weight 
(kg) at birth.
– Macrosomia (%) Defined as a birth weight ≥ 4000 g.
– Neonatal hypoglycemia (%) Defined as a plasma glu-
cose level of less than 30 mg/dl.
– Neonatal Intensive Care Unit admission (NICU 
admission): Defined as the onset of neonatal com-
plications (%) necessitating for intensive care.
57Archives of Gynecology and Obstetrics (2019) 299:55–68 
1 3
– Polyhydramnios (%) Defined as amniotic fluid index 
above the 95th percentile.
– Fetal biometry measures Defined as the (mean) per-
centiles of fetal biparietal diameter (BPD), head cir-
cumference (HC), femur length (FL) and abdominal 
circumference (AC).
• Side effects:
  Any untoward medical occurrence that may present 
during treatment (%).
Study selection and data extraction
Two authors (A.V., G.S.), independently, screened titles and 
abstracts. The full text of all relevant trial reports identified 
through the searching activities was independently exam-
ined. The same authors independently assessed the studies 
for inclusion and extracted data about study features (coun-
try and time of realization of the study), included popula-
tions (participants number and main inclusion criteria), type 
of intervention (drugs and dosage) and study outcomes. If 
more than one study published by the same group was iden-
tified, the corresponding authors were contacted by e-mail 
in order to avoid duplications. One other author (V.B.) inde-
pendently reviewed the selection and data extraction pro-
cess. The results were compared and any disagreement was 
resolved by consensus.
Risk of bias
The risk of bias within studies was assessed independently 
by two authors (A.V., G.S.) following the criteria outlined in 
the Cochrane Handbook for Systematic Reviews of Interven-
tions. Seven domains related to risk of bias were assessed 
in each included trial: (1) random sequence generation; (2) 
allocation concealment; (3) blinding of participants and per-
sonnel; (4) blinding of outcome assessment; (5) incomplete 
outcome data; (6) selective reporting; and (7) other bias. 
Review authors’ judgments were categorized as “low risk”, 
“high risk” or “unclear risk” of bias.
Data analysis
Data analysis was performed by two authors (A.V., G.S.) 
using Review Manager Version 5.3 (The Nordic Cochrane 
Centre, Cochrane Collaboration, 2014, Copenhagen, 
Denmark). Results were compared and differences were 
discussed.
Continuous variables were compared using the means 
(and standard deviations) and expressed as mean differences 
(MD) among Groups (95% CI). Dichotomous variables were 
compared using the odds ratio (OR) with a 95% confidence 
interval (95% CI). Significance level was set at p < 0.05. 
Heterogeneity was measured using I-squared (Higgins I2). 
All analyses were carried out using the random effects model 
(of DerSimonian and Laird, assuming that the patients ana-
lyzed were drawn from a hierarchy of different populations). 
Subgroup analyses were performed to evaluate the specific 
influence of different inositol subtypes (MYO, MYO plus 
DCI, DCI) on pooled ORs and MDs.
We aimed to assess Publication Bias with the use of Fun-
nel plot if at least ten studies were included in the meta-anal-
ysis, according to Cochrane Handbook Recommendations.
Grading of evidence
The evidence was rated by one author (A.V.) using grading 
of recommendations assessment development and evalua-
tion working group (GRADE) methodology (GRADE Pro 
software, available at https ://grade pro.org/). The GRADE 
criteria allow the assessment of a body of evidence in terms 
of study design, risk of bias, indirectness, inconsistency, 
imprecision, large effect size, plausible confounding, dose 
response gradient and publication bias.
The body of evidence was qualified for the following out-
comes: GDM rate, hypertensive disorders, preterm delivery, 
macrosomia, CS rate, neonatal hypoglycemia, and NICU 
admission.
Results
Study selection
After the evaluation of full text, eight studies were excluded 
[6, 15–21]. Finally, a total number of five studies [12, 13, 
22–24] were included in the present meta-analysis (see Fig-
ure S1).
Included studies
The five trials included embedded a total number of 965 par-
ticipants. A summary of main characteristics of the included 
studies is available in Table 1.
Study setting and blinding
Four studies were conducted in Italy [12, 22–24] and one 
study in Ireland [13]. Three were double-center studies [12, 
22, 24] and the remaining two trials were carried out in a 
single center [13, 23]. One study was double-blinded [22]. 
Remaining studies were open label for both clinicians and 
outcomes assessors [12, 13, 23, 24].
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Study drugs
Three studies [12, 23, 24] compared the administration of 
2 g MYO twice/day with placebo; one study [13] evaluated 
the effects of MYO 1100 mg plus DCI (27.6 mg) versus pla-
cebo; another study [22] investigated the effects of 2 g MYO 
plus 400 mg DCI plus 10 mg manganese versus placebo.
Placebo was folic acid (200 µg capsules) in four studies 
[12, 13, 23, 24], while in the study by Malvasi et al. [22] 
placebo content was not clarified.
Type of patients
Four studies included exclusively singleton pregnancies [12, 
13, 23, 24], while in the study by Malvasi et al. [22] the 
number of fetuses was not specified.
Patients’ BMI was between 25 and 30 (kg/m2) in two 
studies [12, 22], ≥ 30 in one study [24] and < 30 in the study 
by D’Anna et al. [23]. In Farren et al. study [13], patients’ 
BMI was variable.
Finally, two studies [13, 23] included only patients with 
familiarity (of first degree) for Type II diabetes.
Diagnosis of gestational diabetes
In four studies [12, 13, 23, 24], diagnosis of GDM was based 
on International Association of Diabetes and Pregnancy 
Study Groups Consensus Panel 2010 criteria [25]. In Mal-
vasi et al.’s study [22], the diagnostic criteria for GDM were 
not specified (GDM rate was not a study outcome).
Assessment of the risk of study BIAS
• Selection bias All but one study [13] (who did not 
provide clear information) used an adequate method 
of random sequence generation (computer generated 
sequence). In one study [23], the method of allocation 
was not reported (unclear risk of bias), whilst remain-
ing studies used an adequate allocation strategy (central 
allocation [24] or sealed envelopes [12, 13, 22]).
• Performance bias All but one study [22] were not blinded 
for both personnel and participants; accordingly, four 
studies were judged at high risk of bias [12, 13, 23, 24].
• Detection bias The outcomes evaluated were unlikely to 
be influenced by the open-label design of the majority of 
studies. Therefore, all studies were judged at low risk of 
bias.
• Attrition bias A drop-out of a small number of partici-
pants occurred in all studies. However, it was judged as 
insubstantial in all but one study [22] (26.1% of drop-
out), according to Cochrane Handbook Recommenda-
tions (“a drop-out not exceeding 20% should not lead to 
substantial bias”).
• Reporting bias Two studies were judged at high risk of 
bias for selective data reporting because the outcomes 
were redesigned after protocol registration [12, 24]. Two 
additional studies were considered at high risk of bias 
because a protocol registration was not reported in the 
manuscript or found in registers [22, 23].
• Other bias All studies were judged at unclear/high risk 
of other bias: In Farren et al.’s study [13], a disparity 
between the pre-defined intervention (in the study pro-
tocol) and the final intervention was observed in terms 
of drug posology (unclear risk of bias). Differently, in 
D’ Anna et al.’s study [23] the percentage of patients 
with a history of GDM (in previous pregnancies) was not 
reported (unclear risk of bias) due to a non-comprehen-
sive description of methods (i.e., timing/number of blood 
pressure measurements) [22]. Finally, two studies [12, 
24] were flawed by a baseline difference in familiarity 
for type II diabetes across groups, potentially affecting 
the effects estimates (Figure S2).
Effects of intervention
ISLs vs no intervention
• Maternal health
– GDM rate Analysis involved a total number of 848 
patients (n = 421 receiving ISLs and n = 427 con-
trols) from four studies [12, 13, 23, 24]. The overall 
results significantly favoured ISLs (OR 0.49, 95% CI 
0.24–1.03, p = 0.01), with high degree of heterogene-
ity across studies (I2 = 73%) (Fig. 1a)
– FG-OGTT, 1HG-OGTT and 2HG-OGTT Four 
studies [12, 13, 23, 24] with 854 participants were 
included (n = 424 receiving ISLs and n = 430 con-
trols). A significant advantage was observed in ISLs 
group concerning FG-OGTT (MD = − 2.62, [95% CI 
− 4.15, − 1.09], p = 0.0008, I2 = 38%), while no dif-
ference was observed in 1HG-OGTT (MD = −6.57, 
[95% CI − 14.24, 1.10], p = 0.09, I2 = 65%) and 
2HG-OGTT (MD = − 5.86, [95% CI − 15.20, 3.48], 
p = 0.22, I2 = 85%) (Fig. 1b–d)
– Weight gain at OGTT Including 608 patients from 
three studies [12, 23, 24], no difference among 
groups was observed (MD = − 0.04, [95% CI − 1.31, 
1.38], p = 0.96, I2 = 82%).
– Hypertensive disorders A total number of 829 
patients (n = 408 receiving ISLs and n = 421 con-
trols) were analyzed from four studies [12, 13, 23, 
24]. A lower pooled prevalence of hypertensive 
disorders was found in ISLs group, which was not 
statistically significant (OR 0.38, 95% CI 0.12–1.16, 
p = 0.09). Inconsistency was low (I2 = 20%) (Fig. 1e)
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(a)
(b)
Fig. 1  Inositol vs placebo for GDM prevention: GDM rate (a), FG-OGTT (b), 1H-OGTT (c), 2H-OGTT (d), hypertensive disorders (e), preterm 
delivery (f)
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– Total cholesterol, LDL, HDL, triglycerides after 
30/60  days Only one study [22] including 48 
patients (n = 24 receiving ISLs and n = 24 con-
trols) reported data about these metabolic mark-
ers. At 30 days, a significant lower concentration 
was observed in total cholesterol (209.54 ± 6.6 vs 
225.79 ± 10.67, p = 0.0001), LDL (141.95 ± 12.57 
vs 154.16 ± 12.04, p = 0.001) and triglycerides 
(154.91 ± 7.44 vs 170.20 ± 10.32, p = 0.0001), but 
not in HDL (p = 0.09). At 60 days, a significant 
lower concentration was observed in Total choles-
terol (185.37 ± 10.8 vs 232.66 ± 8.82, p = 0.0001), 
LDL (124.83 ± 9.90 vs 158.33 ± 11.96, p = 0.0001), 
triglycerides (136.37 ± 7.63vs 175.70 ± 8.85, 
(c)
(d)
Fig. 1  (continued)
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(e)
(f)
Fig. 1  (continued)
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p = 0.0001), as well as in HDL (60.54 ± 10.25vs 
74.33 ± 7.68, p = 0.0001).
– SBP and DBP after 30/60 days Data from one study 
[22] showed a significant difference in SBP after 
30 days (119.16 ± 6.53 vs 121.04 ± 6.91, p = 0.03), 
but not after 60 days (p = 0.12). No difference was 
observed in DBP both at 30 (p = 0.09) and 60 days 
(p = 0.421).
• Delivery outcomes
– CS rate The analysis of 829 patients (n = 408 in ISLs 
group and n = 421 controls) from four studies [12, 
13, 23, 24] did not show any difference in CS rate 
(OR 0.86, 95% CI 0.65–1.13, p = 0.28, I2 = 0%) [24]
– Preterm delivery Data from four studies [12, 13, 
23, 24] about 829 patients (n = 408 in ISLs group 
and n = 421 controls) showed lower prevalence of 
Preterm delivery in ISLs group (OR 0.35, 95% CI 
0.17–0.74, p = 0.006, I2 = 0%) (Fig. 1f)
– Shoulder dystocia The analysis of 829 patients from 
four studies [12, 13, 23, 24] did not show any differ-
ence in shoulder dystocia occurrence (OR 0.57, 95% 
CI 0.12–2.71, p = 0.48, I2 = 0%).
– Third degree perineal tear Only one study reported 
data about perineal lacerations, showing no differ-
ence among ISLs group and Controls (OR 3.05, 95% 
CI 0.31–29.78, p = 0.34).
• Feto-neonatal health
– GA at birth Data from four studies [12, 13, 23, 
24] about 829 patients (n = 408 in ISLs group and 
n = 421 controls) showed no significant difference 
in GA at birth among groups (MD = 1.34, [95% CI 
− 0.18, 2.85], p = 0.08, I2 = 4%).
– Birth weight and Macrosomia The analysis of 
829 patients from four studies [12, 13, 23, 24] 
did not show significant difference in birth weight 
(MD = − 8.65, [95% CI − 140.36, 123.07], p = 0.90, 
I2 = 72%) and Macrosomia (OR 0.62, 95% CI 0.18–
2.11, p = 0.44, I2 = 57%).
– Neonatal hypoglycemia The analysis of 671 patients 
from four studies [12, 13, 23, 24] did not show sig-
nificant difference in neonatal hypoglycemia (OR 
1.86, 95% CI 0.24–14.58, p = 0.55, I2 = 38%).
– NICU admission Data from three studies [12, 13, 
23] including 530 patients did not show difference 
in NICU admission among groups (OR 0.39, 95% CI 
0.13–1.19, p = 0.10, I2 = 0%).
MYO vs no intervention
• Maternal health
– GDM rate Analysis involved a total number of 608 
patients (n = 291 receiving MYO and n = 304 con-
trols) from three studies [12, 23, 24]. The overall 
results significantly favoured ISLs (OR 2.97, 95% 
CI 1.89–4.66, p < 0.00,001), with no heterogeneity 
across studies (I2 = 0%) (Fig. 1a)
– FG-OGTT, 1HG-OGTT and 2HG-OGTT Three 
studies [12, 23, 24] with 614 participants were 
included (n = 304 receiving MYO and n = 310 
Controls). A significant advantage was observed in 
MYO group concerning FG-OGTT (MD = − 3.15, 
[95% CI − 4.43, − 1.87], p < 0.00001, I2 = 0%), 
1HG-OGTT (MD = − 9.86, [95% CI − 14.84, 
− 4.88], p = 0.0001, I2 = 17%) and 2HG-OGTT 
(MD = − 9.64, [95% CI − 17.72, − 1.55], p = 0.02, 
I2 = 73%) (Fig. 1b–d)
– Weight gain at OGTT Data showed in the previous 
section (ISLs vs no intervention).
– Hypertensive disorders A total number of 595 
patients were analyzed from three studies [12, 23, 
24]. No difference among groups was found (OR 
0.40, 95% CI 0.07–2.26, p = 0.30, I2 = 43%) (Fig. 1e)
– Total cholesterol, LDL, HDL, triglycerides, SBP and 
DBP after 30/60 days No study evaluated the meta-
bolic changes associated with MYO administration 
alone.
• Delivery outcomes
– CS rate The analysis of 595 patients (n = 408 in ISLs 
group and n = 421 controls) from four studies [12, 
23, 24] did not show any difference in CS rate (OR 
0.85, 95% CI 0.65–1.13, p = 0.28, I2 = 0%).
– Preterm delivery Data from three studies [12, 23, 
24] about 595 patients showed lower prevalence of 
preterm delivery in MYO group (OR 0.38, 95% CI 
0.16–0.87, p = 0.02, I2 = 0%) (Fig. 1f)
– Shoulder dystocia See the previous section (ISLs vs 
No Intervention).
• Feto-neonatal health
– GA at birth Data from three studies [12, 23, 24] 
about 595 patients showed no significant difference 
in GA at birth among groups (MD = 0.74, [95% CI 
− 1.06, 2.64], p = 0.42, I2 = 0%).
– Birth weight and Macrosomia The analysis of 595 
patients from three studies [12, 23, 24] did not show 
significant difference in birth weight (MD = − 61.29, 
[95% CI − 177.81, 55.23], p = 0.30, I2 = 52%) and 
Macrosomia (OR 0.33, 95% CI 0.06–1.90, p = 0.22, 
I2 = 55%).
– Neonatal hypoglycemia The analysis of 437 patients 
from three studies [12, 23, 24] did not show signifi-
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cant difference in neonatal hypoglycemia (OR 0.53, 
95% CI 0.05–5.22, p = 0.58, I2 = 0%).
– NICU admission Data from two studies [12, 24] 
including 398 patients did not show difference in 
NICU admission among groups (OR 0.33, 95% CI 
0.03–3.89, p = 0.22, I2 = 34%).
MYO plus DCI vs no intervention
• Maternal health
– GDM rate, FG-OGTT, 1HG-OGTT, 2HG-OGTT, 
Weight gain at OGTT and hypertensive disor-
ders No difference was observed regarding GDM 
rate (p = 0.39), FG-OGTT (p = 1.00), 1HG-OGTT 
(p = 0.35)and 2HG-OGTT (p = 0.13), as well as in 
the percentage of hypertensive disorders (p = 0.11) 
[13].
– Total cholesterol, LDL, HDL, triglycerides, SBP and 
DBP after 30/60 days See the section “ISLs vs no 
intervention” (Fig. 1a–e).
• Delivery outcomes
– CS rate, shoulder dystocia, third degree perineal tear 
and preterm delivery No difference was observed for 
all the outcomes evaluated (respectively, p = 0.66, 
p = 0.11, p = 0.34 and shoulder dystocia) (Fig. 1f).
• Feto-neonatal health
– GA at birth, birth weight, macrosomia and NICU 
admission No statistical difference was found among 
groups in all the outcomes evaluated (respectively 
p = 0.07, p = 0.5, p = 0.27, p = 0.51 and p = 0.56).
– Neonatal hypoglycemia Higher rate of hypoglycemia 
was observed in Intervention group in comparison to 
Controls (p = 0.01).
Side effects associated with intervention
Among 411 patients receiving intervention (from all the 
studies included in the review [12, 13, 22–24]), no side effect 
was observed.
Overall quality of evidence
The overall quality of evidence was rated as very low for all 
the outcomes evaluated (Table 2).
The majority of studies were at high risk of reporting 
bias as well as at high risk of bias due to high inconsistency 
and small sample size (i.e. small number of patients and 
events). Moreover, publication bias due to “positive results” 
was strongly suspected.
Discussion
Main findings
Five RCTs were included, with a total number of 965 
participants. Among 411 patients receiving intervention 
(MYO or MYO plus DCI), no side effect was reported.
ISLs supplementation was associated with lower rate 
of GDM, FG-OGTT values, total cholesterol, LDL, tri-
glycerides and in a significant increase of HDL (p < 0.05). 
Contrarily, no difference was observed in 1HG-OGTT, 
2HG-OGTT, weight gain at OGTT, rate of hypertensive 
disorders, SBP and DBP (p = ns).
Regarding the delivery outcomes, we observed lower 
preterm delivery rate in patients receiving ISLs (p < 0.05), 
while no difference was found between groups in terms of 
CS rate, shoulder dystocia and third degree perineal tears 
(p = ns). Finally, regarding feto-neonatal health outcomes, 
no difference among groups was observed in terms of GA 
at birth, birth weight, macrosomia, neonatal hypoglyce-
mia, respiratory distress and NICU admission (p = ns). The 
overall body of evidence was rated as very low (GRADE 
score 1).
The subgroup analysis based on the type of interven-
tion (MYO 2 g twice daily versus MYO 1100 mg plus DCI 
27.6 mg once daily) showed a significant advantage in 
terms of GDM rate, FG-OGTT, 1HG-OGTT, 2HG-OGTT 
and preterm delivery rate in patients receiving 2 g MYO 
twice per day. Contrarily, the daily administration of MYO 
(1100 mg) plus DCI (27.6 mg) did not show any benefit.
Limitations
To our knowledge, the present is the more comprehen-
sive meta-analysis on this topic. However, our findings 
are primarily limited by the methodological flaws of the 
included studies. Moreover, the small sample size included 
in pooled analysis as well as patients’ heterogeneity may 
represent additional sources of bias. Finally, the majority 
of studies were performed in Italy, potentially limiting the 
generalizability of our findings to other ethnic groups.
Implications and biological rationale 
of the intervention
In line with the trend toward older maternal age and rise of 
obesity, the prevalence of GDM has dramatically increased 
during the last 20 years [26, 27]. Because GDM is associ-
ated with high risk obstetric and perinatal complications, 
its spread must be considered as a major public health 
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concern [28, 29]. Due to lack of safe and effective strate-
gies in the prevention of GDM, the identification on novel 
targeted drugs is of critical importance [27–29].
ISLs are simple carbohydrates (belonging to vitamin B 
group) that play a pivotal role in the regulation of many hor-
monal and metabolic pathways in the human body [29, 30]. 
These molecules are ingested daily (as they are contained in 
different natural foods such as cereals, legumes and fruits) 
and their oral supplementation during pregnancy is unlikely 
to generate any appreciable health risk for mother and fetus 
[22, 24].
The most common stereoisomers of ISL, MYO and DCI 
mainly act as insulin-sensitizing agents [8]. Such effect is 
thought to be mainly related to the production of inositol 
glycan secondary messengers, with the enhancement of 
glycogen synthesis and glucose peripheral tissue uptake [5, 
31]. Different insulin-mediated disorders [i.e., type II diabe-
tes (T2D), polycystic ovarian syndrome (PCOS)] have been 
associated with an unbalanced MYO and DCI ratio, perhaps 
due to a reduced ISL epimerase activity (namely, a reduced 
conversion of MYO to DCI) [32–34]. Accordingly, studies 
on women with PCOS and T2D found a significant improve-
ment in terms of insulin resistance after ISLs administra-
tion [35, 36]. These metabolic changes was accompained 
by the restoration of regular periods and higher reproductive 
chances in oligomenorrheic, infertile women [37, 38].
The positive effects of ISL on glucose homeostasis and 
metabolic functions in GDM may be due to comparable bio-
logical reasons to those discussed above. Our results are sup-
ported by a recent murine study (on pregnant mice) showing 
Table 2  Evidence profile: inositol compared to no intervention for gestational diabetes prevention
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is 
a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of 
effect
CI confidence interval, OR Odds ratio
A The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect 
of the intervention (and its 95% CI)
Summary of findings
Inositol compared to no intervention for gestational diabetes prevention
Patient or population: Pregnant women at increased risk of gestational diabetes
Setting: Not applicable
Intervention: Inositol (myo-inositol alone or myo-inositol plus D-chiro inositol)
Comparison: no intervention
Outcomes Anticipated absolute  effectsA (95% CI) Relative effect (95% 
CI)
No of 
participants 
(studies)
Quality of 
the evidence 
(GRADE)
Comments
Risk with no interven-
tion
Risk with inositol
Gestational diabetes 
rate (GDM Rate)
227 per 1.000 126 per 1.000 
(66–232)
OR 0.49 (0.24–1.03) 848 (4 RCTs) ⊕◯◯◯
Very  lowa,b,c
Hypertensive disorders 45 per 1.000 15 per 1.000 (7–37) OR 0.33 (0.14–0.82) 829 (4 RCTs) ⊕◯◯◯
Very  lowa,c,d
Preterm delivery 69 per 1.000 25 per 1.000 (12–50) OR 0.34 (0.16–0.71) 829 (4 RCTs) ⊕◯◯◯
Very  lowa,c,d
Macrosomia 59 per 1.000 38 per 1.000 (11–118) OR 0.62 (0.18–2.11) 829 (4 RCTs) ⊕◯◯◯
Very  lowa,d,e
Cesarean section rate 
(CS rate)
416 per 1.000 380 per 1.000 
(316–446)
OR 0.86 (0.65–1.13) 829 (4 RCTs) ⊕◯◯◯
Very  lowa
Neonatal hypogly-
cemia
9 per 1.000 16 per 1.000 (2–113) OR 1.86 (0.24–14.58) 671 (4 RCTs) ⊕◯◯◯
Very  lowa,d
Neonatal intensive 
care unit admission 
(NICU admission)
34 per 1.000 17 per 1.000 (5–52) OR 0.48 (0.15–1.57) 632 (3 RCTs) ⊕◯◯◯
Very  lowa,d
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that MYO administration was associated with adipose tissue 
markers of improved insulin sensitivity and glucose uptake 
[39]. Moreover, we must stress that all the RCTs included in 
our review found a certain benefit from ISLs, with the excep-
tion of the one by Farren et al. [13]. Such a discrepancy was 
potentially ascribable to the different molecules, dosages and 
regimens adopted in the trial by Farren et al. [13] in compari-
son to other studies [12, 22, 23] (1.1 g MYO plus 27.6 g DCI 
once daily in the study by Farren et [13] al versus 2 g MYO 
twice daily in other studies [12, 22, 23]). At this regard, Orrù 
et al. [40]. recently demonstrated that the half-life of ISLs is 
considerably short (near to 12 h), concluding that 2 g of MYO 
twice per day might be the preferable regimen to guarantee 
24-h drug coverage.
Based on these premises, an adequate administration of 
ISLs may be beneficial for pregnant women at risk for GDM 
[22]. Nevertheless, further studies are needed to better eluci-
date the molecular mechanisms of action of ISLs.
Conclusions
ISLs administration during pregnancy appears to be safe and 
may represent a novel strategy for GDM prevention. In par-
ticular, the daily administration of MYO 2 g twice daily may 
improve the glycemic homeostasis and may reduce GDM rate 
and preterm delivery rate. Due to poor quality of evidence 
available, further robust and good-quality RCTs are still 
needed to confirm the effectiveness and optimal dose of ISLs 
for GDM prevention. Future studies in different settings will 
also assess the potential application of ISLs to other ethnic 
groups.
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